ENP110: Hypercortisolism and T2D

<p><span style="color: rgb(44, 42, 41);">For some people, diabetes can be very hard to control, even with the standard glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. What’s the relationship between type 2 diabetes and hypercortisolism, and what do health care providers need to know about that relationship? To help answer those questions, host Aaron Lohr talks with two guests.&nbsp;</span><strong style="color: rgb(44, 42, 41);">Vivian A. Fonseca, MD</strong><span style="color: rgb(44, 42, 41);">, is a professor of medicine, assistant dean for clinical research, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the section of endocrinology at Tulane University Medical Center in New Orleans.&nbsp;</span><strong style="color: rgb(44, 42, 41);">James W. Findling, MD</strong><span style="color: rgb(44, 42, 41);">, is a professor of medicine and surgery at the Medical College of Wisconsin. Drs. Fonseca and Findling are authors of an article published in the journal&nbsp;</span><em style="color: rgb(44, 42, 41);">Diabetes Care</em><span style="color: rgb(44, 42, 41);">&nbsp;looking at the CATALYST study: “Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.” This episode is made possible by support from Corcept Therapeutics Inc.</span></p>